This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Glycine Treatment of Prodromal Symptoms

This study has been completed.
Stanley Medical Research Institute
Information provided by (Responsible Party):
Yale University Identifier:
First received: December 20, 2005
Last updated: March 28, 2012
Last verified: March 2012
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Condition Intervention Phase
Schizophrenia Drug: glycine Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Glycine Treatment of Prodromal Symptoms

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Scale Of Prodromal Symptoms total score [ Time Frame: 8 weeks ]

Enrollment: 10
Study Start Date: July 2002
Study Completion Date: November 2004
Primary Completion Date: November 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: glycine
0.8 g/kg/day


Ages Eligible for Study:   14 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 14-35
  • meets SIPS criteria for psychosis prodrome

Exclusion Criteria:

  • current antipsychotic medication
  • more than 4 weeks of antipsychotic medication lifetime
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00268749

Sponsors and Collaborators
Yale University
Stanley Medical Research Institute
Principal Investigator: Scott W Woods, MD Yale University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Yale University Identifier: NCT00268749     History of Changes
Other Study ID Numbers: 02T-175
Study First Received: December 20, 2005
Last Updated: March 28, 2012

Additional relevant MeSH terms:
Prodromal Symptoms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Signs and Symptoms
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on September 21, 2017